Related references
Note: Only part of the references are listed.PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation
Nicola Tumino et al.
LEUKEMIA (2020)
A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy
Balamayoora Theivanthiran et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy
Carol M. Amato et al.
CANCERS (2020)
S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes
Pinyang Cheng et al.
LEUKEMIA (2019)
The NLRP3 Inflammasome as a Pharmacological Target
Carlo Marchetti
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2019)
Inhibition of NLRP3 inflammasome in tumor microenvironment leads to suppression of metastatic potential of cancer cells
Hye Eun Lee et al.
SCIENTIFIC REPORTS (2019)
IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients
Richard P. Tobin et al.
FRONTIERS IN ONCOLOGY (2019)
Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation
Irena Kaplanov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
Karen V. Swanson et al.
NATURE REVIEWS IMMUNOLOGY (2019)
OLT1177, a ß-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation
Carlo Marchetti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Rebekka Weber et al.
FRONTIERS IN IMMUNOLOGY (2018)
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Carl Morrison et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis
Carlo Marchetti et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
Douglas B. Johnson et al.
JCI INSIGHT (2018)
On the origin of myeloid-derived suppressor cells
Camilla Rydberg Millrud et al.
ONCOTARGET (2017)
Expression of checkpoint molecules on myeloid-derived suppressor cells
Marlene Ballbach et al.
IMMUNOLOGY LETTERS (2017)
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M. Ridker et al.
LANCET (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
Yago Pico de Coana et al.
ONCOTARGET (2017)
Multiscale Modeling of Inflammation-Induced Tumorigenesis Reveals Competing Oncogenic and Oncoprotective Roles for Inflammation
Yucheng Guo et al.
CANCER RESEARCH (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Alexander Martens et al.
CLINICAL CANCER RESEARCH (2016)
Clinical Significance of Circulating CD33+ CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab
Moshe Sade-Feldman et al.
CLINICAL CANCER RESEARCH (2016)
Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis
Michael Hoelzel et al.
TRENDS IN IMMUNOLOGY (2016)
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
Jeffrey Weber et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Targeting inflammasome/IL-1 pathways for cancer immunotherapy
Beichu Guo et al.
SCIENTIFIC REPORTS (2016)
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Viktor Umansky et al.
VACCINES (2016)
The Nlrp3 Inflammasome Suppresses Colorectal Cancer Metastatic Growth in the Liver by Promoting Natural Killer Cell Tumoricidal Activity
Jeremy Dupaul-Chicoine et al.
IMMUNITY (2015)
Immunity, inflammation, and cancer: an eternal fight between good and evil
Shabnam Shalapour et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
A role for G-CSF and GM-CSF in nonmyeloid cancers
Alexander M. Aliper et al.
CANCER MEDICINE (2014)
Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients
Kimberly R. Jordan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Activation and regulation of the inflammasomes
Eicke Latz et al.
NATURE REVIEWS IMMUNOLOGY (2013)
NLRP3 Suppresses NK Cell-Mediated Responses to Carcinogen-Induced Tumors and Metastases
Melvyn T. Chow et al.
CANCER RESEARCH (2012)
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
Joannes F. M. Jacobs et al.
LANCET ONCOLOGY (2012)
Inflammasome polymorphisms confer susceptibility to sporadic malignant melanoma
Deepti Verma et al.
PIGMENT CELL & MELANOMA RESEARCH (2012)
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Charles A. Dinarello
BLOOD (2011)
Why not treat human cancer with interleukin-1 blockade?
Charles A. Dinarello
CANCER AND METASTASIS REVIEWS (2010)
IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function
Moshe Elkabets et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Constitutively Active Inflammasome in Human Melanoma Cells Mediating Autoinflammation via Caspase-1 Processing and Secretion of Interleukin-1β
Miyako Okamoto et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer
Irving C. Allen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Suzanne Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2009)
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors
Francois Ghiringhelli et al.
NATURE MEDICINE (2009)
Inflammation and melanoma metastasis
Vladislava O. Melnikova et al.
PIGMENT CELL & MELANOMA RESEARCH (2009)
Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling
Joseph A. Duncan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions
Ron N. Apte et al.
CANCER AND METASTASIS REVIEWS (2006)
IL-1 is required for tumor invasiveness and angiogenesis
E Voronov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome
HM Hoffman et al.
NATURE GENETICS (2001)
Inflammation and cancer: back to Virchow?
F Balkwill et al.
LANCET (2001)
Share Paper
